Literature DB >> 1360020

Prolactin bioassay and hyperprolactinemia.

C A Peabody1, P N Schultz, M D Warner, I G Worsley, H G Friesen, N A Samaan.   

Abstract

The Nb2 rat lymphoma bioassay (BA) for prolactin (PRL) was performed in 26 subjects with hyperprolactinemia, 17 of whom had radiologic evidence of a pituitary adenoma. All subjects were treated with the long acting dopamine agonist CV 205-502. The radioimmunoassay (RIA) PRL significantly decreased with treatment but the BA/RIA PRL remained essentially the same, indicating that the relative bioactivity was unaffected.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1360020     DOI： 10.1007/BF03348787

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


  12 in total

1.  A SENSITIVE DOUBLE ANTIBODY IMMUNOASSAY FOR HUMAN GROWTH HORMONE IN PLASMA.

Authors:  D S SCHALCH; M L PARKER
Journal:  Nature       Date:  1964-09-12       Impact factor: 49.962

2.  Prolactin bioassay in medicated schizophrenics.

Authors:  C A Peabody; S W Clitherve; D D Warner; N N Boutros; I G Worsley; H G Friesen
Journal:  Psychiatry Res       Date:  1991-05       Impact factor: 3.222

3.  Serum prolactin bioactivity and immunoactivity in hyperprolactinaemic states.

Authors:  C R Smith; J Butler; I Hashim; M R Norman
Journal:  Ann Clin Biochem       Date:  1990-01       Impact factor: 2.057

4.  Specific effect of CV 205-502, a potent nonergot dopamine agonist, during a combined anterior pituitary function test.

Authors:  R C Gaillard; K Abeywickrama; J Brownell; A F Muller
Journal:  J Clin Endocrinol Metab       Date:  1989-02       Impact factor: 5.958

5.  Serum prolactin and growth hormone determined by radioimmunoassay and a two-site immunoradiometric assay: comparison with the Nb2 cell bioassay.

Authors:  D P Rose; B Berke; L A Cohen
Journal:  Horm Metab Res       Date:  1988-01       Impact factor: 2.936

6.  Correlation and comparison of Nb2 lymphoma cell bioassay with radioimmunoassay for human prolactin.

Authors:  M G Subramanian; N J Spirtos; K S Moghissi; D M Magyar; M F Hayes; R R Gala
Journal:  Fertil Steril       Date:  1984-12       Impact factor: 7.329

7.  Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502.

Authors:  M L Vance; M Lipper; A Klibanski; B M Biller; N A Samaan; M E Molitch
Journal:  Ann Intern Med       Date:  1990-05-01       Impact factor: 25.391

8.  A new sensitive and specific bioassay for lactogenic hormones: measurement of prolactin and growth hormone in human serum.

Authors:  T Tanaka; R P Shiu; P W Gout; C T Beer; R L Noble; H G Friesen
Journal:  J Clin Endocrinol Metab       Date:  1980-11       Impact factor: 5.958

9.  CV 205-502 treatment of hyperprolactinemia.

Authors:  M L Vance; J R Cragun; C Reimnitz; R J Chang; E Rashef; R E Blackwell; M M Miller; M E Molitch
Journal:  J Clin Endocrinol Metab       Date:  1989-02       Impact factor: 5.958

10.  Size heterogeneity of immunoreactive prolactin in patients with prolactinoma.

Authors:  B Allolio; A Hoeppener; U Leonhardt; U Deuss; W Winkelmann
Journal:  Acta Endocrinol (Copenh)       Date:  1987-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.